Comparisons of adalimumab levels and ADAb occurrence between treatment response and inactive disease/remission groups were analysed with the MannWhitneyUtest, 2test or independent samplest-test, as appropriate. of adalimumab originator compared with GP2017. == Conclusion == Higher adalimumab levels were associated with a better response and improved drug survival for all diagnoses, with a suggested lower threshold of 6.0 mg/l for RA/PsA. This finding, the large variability in drug levels among patients receiving standard adalimumab dose and the high proportion of patients developing ADAbs encourages further investigations into the potential role of therapeutic drug monitoring of adalimumab. Keywords:adalimumab, serum drug level, inflammatory joint disease, anti-drug antibodies, TNF inhibitors == Rheumatology key messages. == Higher adalimumab levels were associated with treatment response and improved drug survival across diagnoses. The indicated lower threshold of adalimumab was 6.0 mg/l in RA/PsA. ADAbs were found in 10% of patients, more commonly without methotrexate comedication, reducing treatment effect. == Introduction == TNF- Diosgenin glucoside inhibitors (TNFis) and other biologic drugs have, together with novel treatment strategies such as treat to target, contributed to a revolution in the treatment of inflammatory joint diseases [1]. For patients with RA, PsA and axial SpA (axSpA), remission or inactive disease is now a realistic treatment goal. Nevertheless, despite current therapies and treatment strategies, a large proportion of patients do not respond sufficiently to therapy and approximately half of patients lose efficacy over time [2,3]. Failure to maintain disease control has a major impact on quality of life and increases the risk of joint destruction for patients with peripheral arthritis. Loss of efficacy can be caused by underexposure to drugs, with or without development of anti-drug antibodies (ADAbs) [46]. Therapeutic drug monitoring (TDM), individualized dosing based on assessment of drug levels and ADAbs, Diosgenin glucoside is one strategy suggested to improve the effectiveness of TNFis [7]. TDM provides an opportunity to minimize Diosgenin glucoside both under- and overexposure to drugs. While underexposure can lead to loss of efficacy, overexposure increases costs and may predispose patients to adverse events [8]. In addition, timely identification of ADAbs enables early adjustment of treatment, possibly preventing a clinical flare [9]. In order to develop TDM algorithms, therapeutic ranges for the drug in question must be identified [10]. Recently published EULAR points to consider stated that one important barrier to using TDM in clinical care is the current lack of identified therapeutic ranges for most TNFis Rabbit polyclonal to ZBED5 [10]. Adalimumab, a fully human monoclonal antibody, is the most commonly used TNFi worldwide in the treatment of several immune-mediated inflammatory diseases, including inflammatory joint diseases [11,12]. While prior data suggest that adalimumab levels of 412 mg/l are associated with treatment response in RA and PsA patients [1318], less is known regarding optimal serum adalimumab levels in axSpA [1921]. Adalimumab has a high immunogenic potential, both in originator and biosimilar products, with ADAb development in 1060% of patients, depending on the diagnosis and assay used for detection [6,22]. Except for co-medication with methotrexate, which reduces the occurrence of ADAbs, little is known regarding factors associated with ADAb formation to adalimumab [2325]. The main aim of this study was to explore associations between serum adalimumab levels, treatment response and drug survival in individuals with inflammatory joint diseases, with the intention of identifying a restorative level. This would allow the development of TDM algorithms for adalimumab that can be validated in prospective medical tests. Additionally, we targeted to explore the event, risk factors and medical implications of neutralizing ADAbs. == Methods == == Study human population == The Norwegian Antirheumatic Drug Registry (NOR-DMARD) (clinicaltrials.gov:NCT01581294) is a longitudinal multicentre observational study including adult individuals with inflammatory joint diseases initiating therapy with biologic DMARDs (bDMARDs) [26,27]. Clinical data are authorized at baseline, 3, 6, 9 and 12 months and thereafter every 6 months. Biobank samples are collected at baseline and after 3 months. In the current study we included individuals with a medical analysis of RA, PsA or axSpA with an available serum sample collected 3 months after initiating adalimumab. For assessment of treatment response, medical data from baseline and 3 months were used. Information from your last authorized follow-up check out was used in the.